AUTHOR=Zhang Tongyi , Wang Hongwei , Cai Zhiwei , Zhang Siqi , Jiang Chongyi 

TITLE=RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1078076

DOI=10.3389/fonc.2023.1078076

ISSN=2234-943X

ABSTRACT=<p>Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While <italic>RET</italic> fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with <italic>TRIM33-RET</italic> fusion has not been previously reported. Herein, we presented a case of a 68-year-old man with pancreatic cancer harboring <italic>TRIM33-RET</italic> fusion who responded remarkably to pralsetinib despite being intolerant to chemotherapy. To our knowledge, this is the first report on the clinical value of a single <italic>TRIM33-RET</italic> fusion in pancreatic cancer, which may benefit from the targeted therapy.</p>